![Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof](/docs/US/2021-03-09/US10941151B2/abs.jpg.600x600.jpg)
- Patent Title: Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
-
Application No.: US16880337Application Date: 2020-05-21
-
Publication No.: US10941151B2Publication Date: 2021-03-09
- Inventor: Hamid R. Hoveyda , Guillaume Dutheuil , Graeme Lovat Fraser , Marie-Odile Roy , Mohamed El Bousmaqui , Frederic Batt
- Applicant: Ogeda SA
- Applicant Address: BE Gosselies
- Assignee: Ogeda SA
- Current Assignee: Ogeda SA
- Current Assignee Address: BE Gosselies
- Agency: McCarter & English, LLP
- Agent Maria Laccotripe Zacharakis; Xin Zhang
- Priority: EP11183678 20111003,EP11183679 20111003,EP11183681 20111003,EP11183692 20111003
- Main IPC: C07D241/08
- IPC: C07D241/08 ; C07D487/04
![Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof](/abs-image/US/2021/03/09/US10941151B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.
Public/Granted literature
Information query
